References
- Ahwon L, Woo CP, Hyeon WY, et al (2007). Expression of c-erbB2, cyclin D1 and estrogen receptor and their clinical implications in the invasive ductal carcinoma of the breast. Jpn J Clin Oncol, 37, 708-14. https://doi.org/10.1093/jjco/hym082
- Asghar U, Hawkes E, Cunningham D (2010). Predictive and prognostic biomarkers for targeted therapy in metastatic colorectal cancer. Clin Colorectal Cancer, 9, 274-81. https://doi.org/10.3816/CCC.2010.n.040
- Cacheux W, Le Tourneau C, Baranger B, Mignot L, Mariani P (2011). Targeted biotherapy in metastatic colorectal carcinoma: Current practice. J Visc Surg, 148, 12-8. https://doi.org/10.1016/j.jviscsurg.2010.12.004
- Christos NP, Christopher JL (2004). Bortezomib as a potential treatment for prostate cancer. Cancer Res, 64, 5036-43. https://doi.org/10.1158/0008-5472.CAN-03-2707
- Chua W, Moore MM, Charles KA, Clarke SJ (2009). Predictive biomarkers of clinical response to targeted antibodies in colorectal cancer. Curr Opin Mol Ther, 11, 611-22.
- Colakoglu T, Yildirim S, Kayaselcuk F, et al (2008). Clinicopathological significance of PTEN loss and the phosphoinositide 3-kinase/Akt pathway in sporadic colorectal neoplasms: is PTEN loss predictor of local recurrence? Am J Surg, 195, 719-25. https://doi.org/10.1016/j.amjsurg.2007.05.061
- Des GG, Uzzan B, Nicolas P, et al (2006). Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br J Cancer, 94, 1823-32. https://doi.org/10.1038/sj.bjc.6603176
- Hawkes E, Cunningham D (2010). Relationship between colorectal cancer biomarkers and response to epidermal growth factor receptor monoclonal antibodies. J Clin Oncol, 28, 529-31. https://doi.org/10.1200/JCO.2010.29.5626
- Herreros-Villanueva M, Rodrigo M, Claver M, et al (2011). KRAS, BRAF, EGFR and HER2 gene status in a Spanish population of colorectal cancer. Mol Biol Rep, 38, 1315-20. https://doi.org/10.1007/s11033-010-0232-x
- Jalba CS, Jalba BA, Nicula C, et al (2011). Clinical relevance of vascular endothelial growth factor-A in colorectal cancer. Rom J Morphol Embryol, 52, 775-81.
- Jemal A, Siegel R, Ward E, et al (2008). Cancer statistics, 2008. CA Cancer J Clin, 58, 71-96. https://doi.org/10.3322/CA.2007.0010
- Klos KS, Wyszomierski SL, Sun M, et al (2006). ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/ p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells. Cancer Res, 66, 2028-37. https://doi.org/10.1158/0008-5472.CAN-04-4559
- Li Q, Wang D, Li J, Chen P (2011). Clinicopathologic and prognostic significance of HER-2/neu and VEGF expression in colon carcinoma. BMC Cancer, 11, 277. https://doi.org/10.1186/1471-2407-11-277
- Lohrum MA, Woods DB, Ludwig RL, Balint E, Vousden KH (2001). C-terminal ubiquitination of p53 contributes to nuclear export. Mol Cell Biol, 21, 8521-32. https://doi.org/10.1128/MCB.21.24.8521-8532.2001
- Longo R, Gasparini G (2007). Challenges for patient selection with VEGF inhibitors. Cancer Chemother Pharmacol, 60, 151-70. https://doi.org/10.1007/s00280-006-0403-6
- Munro AJ, Lain S, Lane DP (2005). p53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer, 92, 434-44.
- Murad JC, Ribeiro U Jr, Safatle-Ribero AV, et al (2007). Evaluation of moleculer markers in hepatic metastasis of colorectal adenocarcinoma. Hepatogastroenterology, 54, 1029-33.
- Perrone G, Santini D, Verzì A, et al (2006). COX-2 expression in ampullary carcinoma: correlation with angiogenesis process and clinicopathological variables. J Clin Pathol, 59, 492-6. https://doi.org/10.1136/jcp.2005.030098
- Pohl M, Werner N, Munding J, et al (2011). Biomarkers of antiangiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature. Z Gastroenterol, 49, 1398-406. https://doi.org/10.1055/s-0031-1281752
- Sarmadi S, Izadi-Mood N, Sotoudeh K, Tavangar SM (2009). Altered PTEN expression; a diagnostic marker for differentiating normal, hyperplastic and neoplastic endometrium. Diagn Pathol, 4, 41. https://doi.org/10.1186/1746-1596-4-41
- Yang W, Klos K, Yang Y, et al (2002). ErbB2 overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human breast carcinoma. Cancer, 94, 2855-61. https://doi.org/10.1002/cncr.10553
- Van CE, Kohne CH, Lang I, et al (2011). Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol, 29, 2011-9. https://doi.org/10.1200/JCO.2010.33.5091
- Wei Q, Shui Y, Zheng S, et al (2011). EGFR, HER2 and HER3 expression in primary colorectal carcinomas and corresponding metastases: Implications for targeted radionuclide therapy. Oncol Rep, 25, 3-11.
- Wong R, Cunningham D (2008). Using predictive biomarkers to select patients with advanced colorectal cancer for treatment with epidermal growth factor receptor antibodies. J Clin Oncol, 26, 5668-70. https://doi.org/10.1200/JCO.2008.19.5024
- Yen L, Benlimame N, Nie ZR, et al (2002). Differential regulation of tumor angiogenesis by distinct ErbB homo-and heterodimers. Mol Biol Cell, 13, 4029-44. https://doi.org/10.1091/mbc.E02-02-0084
- Yen L, You XL, Al Moustafa AE, et al (2000). Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis. Oncogene, 19, 3460-9. https://doi.org/10.1038/sj.onc.1203685
- Zhou YJ, Xiong YX, Wu XT, et al (2004). Inactivation of PTEN is associated with increased angiogenesis and VEGF overexpression in gastric cancer. World J Gastroenterol, 10, 3225-9.
Cited by
- Lack of Effects of HER-2/neu on Prognosis in Colorectal Cancer: a Meta-analysis vol.15, pp.14, 2014, https://doi.org/10.7314/APJCP.2014.15.14.5551
- Predictive tissue biomarkers for bevacizumab-containing therapy in metastatic colorectal cancer: an update vol.15, pp.3, 2015, https://doi.org/10.1586/14737159.2015.993972
- Platelet Derived Growth Factor-B and Human Epidermal Growth Factor Receptor-2 Polymorphisms in Gall Bladder Cancer vol.16, pp.14, 2015, https://doi.org/10.7314/APJCP.2015.16.14.5647
- Biomarkers of Angiogenesis in Colorectal Cancer vol.7s1, pp.1179-299X, 2015, https://doi.org/10.4137/BIC.S25250
- HDAC inhibitors show differential epigenetic regulation and cell survival strategies on p53 mutant colon cancer cells pp.1538-0254, 2017, https://doi.org/10.1080/07391102.2017.1302820